996 Combination therapy of peginterferon alfa-2A (40KD) (PEGASYS(R)) and ribavirin (COPEGUS(R)) significantly enhance sustained virological and biochemical response rate in chronic... von Shobokshi, O.A., Serebour, F.E., Skakni, L., Al-Jasser, N., Tantawi, A.O., Sabah, A., Dinish, T., Al-Quaiz, M., Qahtani, K., Sandokji, A., Al-Blowi, A., Al-Karawi, M., Al-Kayyal, B., Al-Momen, S., Akbar, H., Ayoola, A., El-Hazmi, M., Humaida, A., El-Hazmi, I., Eissa, H., Khawajah, F., Al-Khalifa, M.

Volltext

Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40KD)/RBV von Shobokshi, O., Serebour, F.E., Skakni, L., Al-Jasser, N., Tantawi, A.O., Sabah, A., Dinish, T., Al-Quaiz, M., Qahtani, K., Sandokji, A., Al-Blowi, A., Al-Karawi, M., Al-Kayyal, B., Al-Momen, S., Akbar, H., Ayoola, A., El-Hazmi, M., Humaida, A., El-Hazmi, I., Eissa, H., Khawajah, F., Al-Khalifa, M.

Volltext